Comparison between Indira IVF IPO and Nephrocare Health IPO.
Indira IVF IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Nephrocare Health IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Indira IVF IPO is up to ₹0.00 Cr whereas the issue size of the Nephrocare Health IPO is up to ₹871.05 Cr. The final issue price of Indira IVF IPO is and of Nephrocare Health IPO is ₹460.00 per share.
| Indira IVF IPO | Nephrocare Health IPO | |
|---|---|---|
| Face Value | ₹2 per share | |
| Issue Price (Lower) | ₹438.00 per share | |
| Issue Price (Upper) | ₹460.00 per share | |
| Issue Price (Final) | ₹460.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ₹41.00 per share | |
| Market Lot Size | 32 shares | |
| Fresh Issue Size | 0 shares | 76,89,918 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹353.60 Cr |
| OFS Issue Size | 0 shares | 1,12,53,102 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹517.45 Cr |
| Issue Size Total | 0 shares | 1,89,43,020 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹871.05 Cr |
Indira IVF IPO opens on , while Nephrocare Health IPO opens on Dec 10, 2025. The closing date of Indira IVF IPO and Nephrocare Health IPO is , and Dec 12, 2025, respectively.
| Indira IVF IPO | Nephrocare Health IPO | |
|---|---|---|
| Anchor Bid Date | Dec 09, 2025 | |
| Issue Open | Dec 10, 2025 | |
| Issue Close | Dec 12, 2025 | |
| Basis Of Allotment (Tentative) | Dec 15, 2025 | |
| Initiation of Refunds (Tentative) | Dec 16, 2025 | |
| Credit of Share (Tentative) | Dec 16, 2025 | |
| Listing date (Tentative) | Dec 17, 2025 | |
| Anchor Lockin End date 1 | Jan 13, 2026 | |
| Anchor Lockin End date 2 | Mar 14, 2026 |
Indira IVF IPO P/E ratio is , as compared to Nephrocare Health IPO P/E ratio of 63.52.
| Indira IVF IPO | Nephrocare Health IPO | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials (Restated Consolidated)Nephrocare Health Services Ltd.'s revenue increased by 34% and profit after tax (PAT) rose by 91% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 78.90 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 71.49 | ||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 63.52 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹4615.34 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 13.45% | ||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 18.67% | ||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.24 | ||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 13.19% | ||||||||||||||||||||||||||||||||||||||||||||||||
In the Indira IVF IPO Retail Individual Investors (RII) are offered while in Nephrocare Health IPO retail investors are offered . Qualified Institutional Buyers (QIB) are offered in Indira IVF IPO and 37,71,946 shares in Nephrocare Health IPO.
| Indira IVF IPO | Nephrocare Health IPO | |
|---|---|---|
| Anchor Investor Reservation | 56,57,919 shares | |
| Market Maker Reservation | 0 shares | |
| QIB | 37,71,946 shares | |
| NII | 28,28,960 shares | |
| RII | 66,00,907 shares | |
| Employee | 83,532 shares | |
| Others | ||
| Total | 1,89,43,264 shares |
Indira IVF IPO subscribed in total, whereas Nephrocare Health IPO subscribed 14.08x.
| Indira IVF IPO | Nephrocare Health IPO | |
|---|---|---|
| QIB (times) | 26.82x | |
| NII (times) | 24.77x | |
| Big NII (times) | 30.43x | |
| Small NII (times) | 13.46x | |
| RII (times) | 2.36x | |
| Employee (times) | 2.81x | |
| Other (times) | ||
| Total (times) | 14.08x |
